In the future, what will be the most sunrise industry?

In this last few years of the 20th century, many people may not hesitate to give you an answer – the Internet!

Yes, the Internet is indeed the most lucrative industry in the next century...... One, yes, is "one"!

There is no doubt that with the current state of the Internet tide one after another, as long as anyone with a little vision knows, this is a super sunrise industry in the future. Otherwise, why would the "capital dads" rush in one by one as if they were crazy, waving dollars? You don't really think that these capitalists are all "stupid", do you?

Hehe, don't be funny!

If you don't blow it up, these people will definitely have a higher IQ than a large number of people? They will not think of things that ordinary people can think of? Even these "capital dads" think much more far-reaching than you.

In the end, it turns out that the "foresight" of these "capital fathers" is indeed correct, and the Internet has indeed become the best industry for "creating wealth" in the next century. Let's not talk about anything else, let's just talk about how many multimillionaires and billionaires were born in the Internet industry?—— countless. Even, just look at how many of the richest people were born in the Internet industry, you can know how sunny the future of this industry is.

It is no exaggeration to say that only by grasping the Internet industry can we grasp the future.

Therefore, Su Chenyu made the Pioneer Fund attack frantically in the Internet industry, and successively ate the shares of Amazon, eBay, Adobe and other Internet companies. In addition, Su Chenyu also asked the Pioneer Fund to keep a close eye on Silicon Valley and Stanford University, and Google, the future Internet leader, must be won no matter what.

Yes, the Internet industry is indeed very sunny, but there is one industry that is no worse than the Internet industry, and that is the biopharmaceutical industry.

You must know that the future era is not only an Internet era, but also a biological era. While artificial intelligence, big data, cloud computing, etc. are guiding the future development direction, biopharmaceutical technologies such as gene sequencing and treatment of terminal diseases such as cancer and AIDS have added a protective shield to this development.

Let's put it this way, the Internet and biopharmaceuticals are the two optimus pillars of the future era!

Therefore, Su Chenyu not only wants the Internet, the pillar of optimism, but also wants to hold the big thick leg of biopharmaceuticals in his arms. This is why the Pioneer Fund has fully taken over the Internet assets of the Ginkgo Fund, which is very simple, Su Chenyu has high hopes for the Ginkgo Fund.

In Su Chenyu's plan, after completely withdrawing from the Internet industry, Ginkgo Fund will enter the biopharmaceutical industry - another pillar of optimism, and he will not give up.

As a high-tech, high-tech, and knowledge-intensive industry that is more high-tech than the Internet, biopharmaceuticals is definitely not an industry that anyone can play. Of course, if you think that a certain field hospital is also considered a biopharmaceutical industry, then there is no need to say it, because that thing can even play 66 with a "barefoot doctor". Besides, didn't a certain field hospital start from "barefoot doctors" and "Jianghu Langzhong"?

Su Chenyu naturally doesn't want to be the kind of "spicy chicken" of a certain field, what he wants to do is a real biomedical giant.

Su Chenyu is full of confidence in becoming a biomedical giant from a nobody, after all, who calls them local tyrants - rich, not ordinary rich, really rich.

It is not too simple for a rich "capital father" to do one thing, and in this era, capital is the source of power to promote social development. Especially for the "gold-swallowing monster" of the biomedical industry, the funds needed are not one or two points, but piles and piles. Don't think that now the "capital dads" are waving money and rushing into the Internet industry, millions or tens of millions of dollars to invest in an Internet company looks crazy, hehe, compared to the biomedical industry, it is really a small thing.

You must know that it is very common for the biomedical industry to invest tens of millions of dollars, or even hundreds of millions of dollars, to research a new biotechnology or develop a new drug. Therefore, which of the giants who can really play the biomedical industry does not have the support of "big financiers" or consortia? The most famous is Johnson & Johnson, behind them is the famous Johnson & Johnson family, of course, the Johnson & Johnson family also rose because of Johnson & Johnson, but who made the family rise early.

In the current biopharmaceutical industry, if you want to do it, you have to throw money, crazy money-this is not too easy for Su Chenyu - in a word, buddy has nothing else, just money.

As the first shot of Ginkgo Fund to break into the biopharmaceutical industry, Su Chenyu did not choose a difficult bone for him, but picked a relatively easy to pinch "soft persimmon" - Amgen.

Compared with super giants such as Pfizer, Johnson & Johnson, and Roche, after all, Amgen is only a young company established less than 20 years ago, and compared with those super biomedical giants that have been around for nearly 100 years, he is simply a small character, and can even be said to be a grandchild.

The most important thing is that compared to supergiants like Johnson & Johnson and Pfizer, Amgen is really too short of money, yes, it is too short of money. Even, in order for the company to survive, Amgen actually raised funds through public shares three times in 1983, 1986 and 1987, which is really poor to a certain extent.

It can't be helped, who made Amgen really have some congenital deficiencies from the beginning, Amgen was founded in 1980 and was a gadget made by a group of scientists and venture capitalists. Therefore, when it began to operate in 1981, Amgen's start-up capital was only a pitiful $19 million, which was quite painful, so I asked you that 19 million was enough to dry yarn? You know, Pfizer and Johnson & Johnson's investment in new drug and new technology research and development projects is in the unit of 100 million, so the $19 million is indeed a bit chilling.

There was no doubt that the $19 million was not enough, so in the course of its subsequent development, Amgen made a rather loss-making deal - selling all the overseas sales of its biotech drug EPO to Johnson & Johnson, thus obtaining a life-saving $19 million in financing.

What to say about this deal, you say that he loses, Amgen is indeed a big loss, because the overseas sales of EPO can bring Johnson & Johnson billions of dollars in revenue every year, while Amgen can only get a pitiful few percent. However, speaking of which, Amgen is not a loss, because it is precisely because of Johnson & Johnson's $19 million life-saving money that it has a biomedical giant with a market value of hundreds of billions of dollars in the future.

Although, in recent years, with the success of the two ace biotech drugs, EPO and G-CSF, Amgen has finally gained a firm foothold, and in 1992, sales exceeded $1 billion.

Fortunately, Amgen hasn't really risen yet, with a market capitalization of just $3 billion, but, you read that right, it's less than $3 billion. Yes, Amgen, which will have a market value of more than $130 billion in the future, is now a "little scumbag" with a market value of less than $3 billion. However, the market value of this point has increased dozens of times compared to when Amgen was first listed.

So, this is really the best opportunity for the Ginkgo fund, and in addition to that, there is another very favorable condition - Goldman Sachs and Lehman Brothers are both shareholders of Amgen.

Yes, Goldman Sachs and Lehman Brothers were coincidentally involved in Amgen's several share financings, so this is quite useful for this raid by Ginkgo Fund.

In fact, there is another important reason why Ginkgo Fund is targeting Amgen, that is, this gadget has not been favored by those consortium funds, and there is no such strong competition. Although Su Chenyu is not afraid of getting involved with consortium funds in the United States, however, more things are better than less things, everyone is seeking money. However, Amgen is such a "golden egg", who dares to rob him, Su Chenyu doesn't mind letting him know why the flowers are so red? Even Morgan and Rockefeller can't do it, it's a big deal, everyone broke up, and at that time, Su Chenyu fell directly to the Rothschilds, after all, who is not making money?

Amgen's major shareholders are venture capitalists, and it's not easy for them to deal with it, only U.S. dollars are enough. Therefore, as soon as the Ginkgo Fund came up, it was carried out with great fanfare according to the strategy set by Su Chenyu for them, that is, to throw money.

Isn't Amgen's market capitalization less than $3 billion? If it doesn't work, it's $3.5 billion, if it doesn't, it's $4 billion, and if it doesn't, it goes up to $5 billion -- that's a bit too much

The valuation of $5 billion is really sky-high, and it smashed the small hearts of many shareholders of Amgen at once.

So, in this case, if anyone is still not satisfied, just ask you if you still have "lewdness"? At this price, just ask what do you want?

Facts have proved that these venture capitalists are still more knowledgeable, or on the road, or they can be said to be unresolute, and under the temptation of $5 billion, they have reached an acquisition agreement with Ginkgo Fund.

With the US dollar banknote to open the way, everything is so smooth, after the $3.5 billion astronomical capital is smashed, the shares in the hands of Ginkgo Fund have reached 70%, if you count the total of nearly 8% of the shares in the hands of Goldman Sachs and Lehman Brothers, hehe, do you need to ask?

At this point, Ginkgo Fund raided Amgen and took the first step into the era of biomedicine......